Global Endometriosis Drugs Market Size By Product(Hormonal Therapy, Add-back Medication, Progestogens), By Application(Hospitals, Clinics, Research Institutes), By Geographic Scope And Forecast

Endometriosis Drugs Market Size And Forecast

Endometriosis Drugs Market size is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2021 to 2028.

The growing prevalence of endometriosis has also lead to higher awareness among women related to endometriosis treatment. Moreover, the significant rise in the occurrence of this disease, investment in research, and development are also increasingly expanding growth opportunities in this market. The Global Endometriosis Drugs Market report provides a holistic evaluation of the market. The report offers comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Endometriosis Drugs Market Definition

Endometriosis is a chronic and painful condition, where the tissues that outline the uterus externally (found in the fallopian tubes, ovaries, and ligaments that support the uterus) ruptures and causes inflammation and internal bleeding. This can cause infertility, adhesions, pain, scar tissue formation, and bowel problems. Symptoms of the disease include painful bowel movements during periods, pain with sex, pain before and during periods, infertility, painful urination during periods, fatigue, and other gastrointestinal problems such as diarrhea, nausea, and constipation. Endometriosis is a lifelong condition so it is important to develop a medical strategy to manage it based on the extent of the disease, severity of pain, and potential plans for pregnancy.

There are various medications available to cure endometriosis such as Pain Medication, Hormone Birth Control, Progestin-only contraceptives, Gonadotroin-releasing Hormone (GnRH) Analogues, and Aromatase Inhibitors. Aromatase is a chemical that boosts your body's estrogen production. Aromatase inhibitors block it, which lowers your estrogen level. These medicines aren't routinely used to treat endometriosis. Whereas, hormone birth control can stop the heavy menstrual bleeding that generally accompanies endometriosis.

Global Endometriosis Drugs Market Overview

The growing focus emphasis on women's health is the key factor in boosting the growth of the endometriosis drugs market size during the forecast period. The various governmental authorities and organizations are working to raise awareness to overcome unawareness and uneducated challenges problems. The focus on women's health will lead to the expansion of the global endometriosis drugs market. Moreover, the significant rise in the occurrence of this disease, investment in research, and development has positively anticipated in propelling the growth of the global Endometriosis drugs market.

There are certain restraints and challenges faced which will hinder the overall market growth. The factors such as the endometriosis drug market are dominated by high-cost hormone-based therapeutics, which is a significant concern for patients and is estimated to sluggish growth during the forecast period. Lack of awareness about various gynecological cancer indications such as endometriosis and endometrial cancer was a challenge for the growth of the market. Further, the time that is taken to diagnose the disease is high, which is estimated by the researchers as seven to nine years. Till now, there are no diagnostic tests available that are non-invasive coupled with a lack of medical infrastructure and hi-tech medical equipment and devices. These are the potential restraints hampering the overall growth of the global Endometriosis drugs market.

Global Endometriosis Drugs Market: Segmentation Analysis

Global Endometriosis Drugs Market is segmented based on Product, Application, And Geography.

Endometriosis Drugs Market by Product

• Hormonal Therapy
• Add-back Medication
• Progestogens
• Chinese Herbs

Based on Product, the market is bifurcated into Hormonal Therapy, Add-back Medication, Progestogens, and Chinese Herbs. The hormone therapy segment holds the largest market share for the forecast period. It is considered the most effective treatment for endometriosis as it can reduce or effectively eliminate the pain associated with the condition compared with analgesics. This factor will increase sales of medications that act on hormones associated with the condition. The sales of hormonal medications will further improve with the introduction of novel drug delivery systems.

Endometriosis Drugs Market by Application

• Hospitals
• Clinics
• Research Institutes

Based on Application, the market is bifurcated into Hospitals, Clinics, Research Institutes. The hospital segment is estimated to witness the highest CAGR for the forecast period. The factors that can be attributed to the growing prevalence of endometriosis and rise in the occurrence of this disease are fueling the demand for this segment.

Endometriosis Drugs Market by Geography

On the basis of regional analysis, the Global Endometriosis Drugs Market is classified into

North America

Europe

Asia Pacific

Rest of the world

North America holds the largest market share. The increasing treatment costs, higher disability losses, and the large number of reproductive populations that are suffering from endometriosis. High awareness among people, strong governmental initiatives and ongoing projects will boost the market in this region.

Key Players

The market analysis entails a section solely dedicated to major players in the Global Endometriosis Drugs Market wherein our analysts provide an insight into the financial statements of all the major players along with its key developments product benchmarking and SWOT analysis. The company profile section also includes a business overview and financial information. The companies that are provided in this section can be customized according to the client's requirements.

• AbbVie
• Astellas Pharma
• AstraZeneca
• Debiopharm Group
• Evotec AG
• Kissei Pharmaceutical
• Neurocrine Biosciences
• ObsEva
• Pfizer
• Repros Therapeutics
• Roivant Sciences GmbH
• Takeda Pharmaceutical Company Limited
• ValiRx

Key Developments

Partnerships, Collaborations and Agreements

• The US Food and Medication Administration (FDA) granted AbbVie Inc. approval for their drug ORILISS in July 2018. (elagolix). This is a GnRH-type medication that is used to relieve endometriosis pain that is severe to moderate.
• In July 2017, Evotec AG reported that a programme from their multi-target endometriosis alliance with Bayer had moved into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec.
• In January 2021, Myovant Sciences and Pfizer Inc. announced that the Phase 3 SPIRIT long-term extension study of the investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with endometriosis found clinically significant reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain over a year.

Product Launches and Product Expansions

• In October 2018, Astellas Pharma Inc. reported that building and remodelling of new facilities for the research, development, and manufacture of novel pharmaceuticals employing new Modality/Technology had commenced in Toyama and Tsukuba, Japan, as well as Massachusetts, USA.